Likewise, the CDK4 R24C point mutation confers selective growth advantage by causing loss of CDK4 binding to p16INK4a, and consequently constitutive activation of CDK4 in familial melanoma and in a subset of lung cancers and lymphomas [173,174,175,178,179,238]. Here, CDKN2A is linked to lung carcinoma.